BR112019002151A2 - usos de compostos de fórmula (i) e usos de uma composição - Google Patents

usos de compostos de fórmula (i) e usos de uma composição

Info

Publication number
BR112019002151A2
BR112019002151A2 BR112019002151A BR112019002151A BR112019002151A2 BR 112019002151 A2 BR112019002151 A2 BR 112019002151A2 BR 112019002151 A BR112019002151 A BR 112019002151A BR 112019002151 A BR112019002151 A BR 112019002151A BR 112019002151 A2 BR112019002151 A2 BR 112019002151A2
Authority
BR
Brazil
Prior art keywords
compounds
formula
composition
treatment
nash
Prior art date
Application number
BR112019002151A
Other languages
English (en)
Inventor
Baverel Gabriel
Moinet Gérard
Original Assignee
Metabolys
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolys filed Critical Metabolys
Publication of BR112019002151A2 publication Critical patent/BR112019002151A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)

Abstract

a presente invenção se refere aos compostos de fórmula (i), ou aos seus enantiômeros, diastereômeros e os seus sais de adição com bases ou ácidos farmaceuticamente aceitáveis, para a utilização na prevenção ou tratamento, de preferência, o tratamento de nash.
BR112019002151A 2016-08-04 2017-08-03 usos de compostos de fórmula (i) e usos de uma composição BR112019002151A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16306010.6A EP3278802A1 (en) 2016-08-04 2016-08-04 New treatment for the non alcoholic steatohepatitis and fibrosis
PCT/EP2017/069595 WO2018024805A1 (en) 2016-08-04 2017-08-03 New treatment for the non alcoholic steatohepatitis and fibrosis

Publications (1)

Publication Number Publication Date
BR112019002151A2 true BR112019002151A2 (pt) 2019-05-14

Family

ID=56683865

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019002151A BR112019002151A2 (pt) 2016-08-04 2017-08-03 usos de compostos de fórmula (i) e usos de uma composição

Country Status (11)

Country Link
US (1) US11324743B2 (pt)
EP (2) EP3278802A1 (pt)
JP (1) JP2019523288A (pt)
KR (1) KR20190034642A (pt)
CN (1) CN109661231B (pt)
AU (1) AU2017307341A1 (pt)
BR (1) BR112019002151A2 (pt)
CA (1) CA3032607A1 (pt)
RU (1) RU2762280C2 (pt)
WO (1) WO2018024805A1 (pt)
ZA (1) ZA201900707B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102177304B1 (ko) * 2018-07-23 2020-11-10 제이투에이치바이오텍 (주) 비알콜성 지방간염의 예방 또는 치료용 약학 조성물
WO2021073643A1 (zh) * 2019-10-18 2021-04-22 正大天晴药业集团股份有限公司 用于治疗非酒精性脂肪性肝炎的药物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002100341A2 (en) * 2001-06-12 2002-12-19 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
FR2902426B1 (fr) * 2006-06-19 2008-09-05 Pierre Fabre Medicament Sa Derives de cinnamoyl-piperazine
US20080194575A1 (en) * 2006-10-04 2008-08-14 Naiara Beraza Treatment for non-alcoholic-steatohepatitis
WO2009151116A1 (ja) * 2008-06-13 2009-12-17 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬
EP2573081B1 (en) 2010-05-19 2017-07-12 Kowa Company Ltd. Prophylactic and/or therapeutic agent for non-alcoholic steatohepatitis
WO2012017515A1 (ja) 2010-08-03 2012-02-09 ミライアル株式会社 マイクロ流路デバイス
FR2976943B1 (fr) * 2011-06-23 2013-07-12 Metabolys Derives de piperazine, leurs procedes de preparation et leurs utilisations dans le traitement de l'insulinoresistance
FR2976942B1 (fr) * 2011-06-23 2013-07-12 Metabolys Derives de piperazine, leurs procedes de preparation et leurs utilisations dans le traitement de l'insulinoresistance
FR2999427B1 (fr) 2012-12-17 2015-01-30 Metabolys Composition et kit comprenant des derives de piperazine et de la metformine, leur utilisation dans le traitement du diabete

Also Published As

Publication number Publication date
EP3278802A1 (en) 2018-02-07
CN109661231A (zh) 2019-04-19
WO2018024805A1 (en) 2018-02-08
RU2019105810A3 (pt) 2020-09-04
CA3032607A1 (en) 2018-02-08
RU2762280C2 (ru) 2021-12-17
KR20190034642A (ko) 2019-04-02
RU2019105810A (ru) 2020-09-04
CN109661231B (zh) 2021-08-24
JP2019523288A (ja) 2019-08-22
US20190160057A1 (en) 2019-05-30
AU2017307341A1 (en) 2019-02-21
US11324743B2 (en) 2022-05-10
EP3493806A1 (en) 2019-06-12
ZA201900707B (en) 2022-04-28

Similar Documents

Publication Publication Date Title
BR112016016844A2 (pt) Compostos heterocíclicos
UY36371A (es) Compuestos de indolcarboxamida inhibidores de quinasas tipo btk y tipo tec
BR112016020199A8 (pt) composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
PH12018502307A1 (en) Aromatic sulfonamide derivatives
MD4800B1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
EA201891917A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов irak4
BR112017010893A2 (pt) análogos de ácidos biliares como agonistas de fxr/tgr5 e métodos de uso dos mesmos
BR112018070123A2 (pt) oxiesterós e métodos de uso dos mesmos
DOP2015000082A (es) Inhibidores no nucleósidos de la transcriptasa inversa
BR112018015273A2 (pt) derivados de benzimidazol como moduladores de ror-gama
BR112016015983A2 (pt) Compostos de indazol como inibidores de irak4, seus usos, e composição farmacêutica
BR112015021888A8 (pt) inibidores de dna-pk, seus usos e composição farmacêutica
BR112018073524A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição.
BR112017023740A2 (pt) ?forma sólida de um composto, processo para a preparação de uma forma sólida, composição farmacêutica, método para o tratamento ou prevenção de doenças e utilização de uma forma sólida?
NI201200146A (es) Inhibidores no nucleosídicos de la transcriptasa inversa
MX2016012175A (es) Nuevos compuestos.
BR112018006545A2 (pt) ?composto, composição farmacêutica, combinação, uso de um composto, e, método para tratamento de uma doença ou condição?
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih
BR112017009012A2 (pt) derivados de anel benzo de seis membros como inibidor de dpp-4 e seu uso
BR112017023959A2 (pt) novos compostos de sulfonimidoilpurinona e derivados para o tratamento e profilaxia de infecção por vírus
BR112016022722A2 (pt) pró-fármacos de inibidores da transcriptase reversa de hiv
BR112018002689A2 (pt) composto, composição útil e método para tratamento de infecção por hiv
CR20180091A (es) 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del vih
CL2021002309A1 (es) Compuestos útiles en la terapia del vih
BR112020008258B8 (pt) Compostos de biarila substituída ou seus sais farmaceuticamente aceitáveis, sua composição e seu uso como inibidores de indoleamina 2,3-dioxigenase (ido)

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements